DONALDSON Co INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that DONALDSON Co INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Jul 31, 2019 | $726.90M | Sep 27, 2019 |
| FY2019 | Apr 30, 2019 | $712.80M | Sep 27, 2019 |
| FY2019 | Jan 31, 2019 | $703.70M | Sep 27, 2019 |
| FY2019 | Oct 31, 2018 | $701.40M | Sep 27, 2019 |
| FY2018 | Jul 31, 2018 | $724.70M | Oct 1, 2018 |
| FY2018 | Apr 30, 2018 | $700.00M | Oct 1, 2018 |
| FY2018 | Jan 31, 2018 | $664.70M | Oct 1, 2018 |
| FY2018 | Oct 31, 2017 | $644.80M | Oct 1, 2018 |
| FY2018 | Jul 31, 2017 | $660.10M | Oct 1, 2018 |
| FY2018 | Apr 30, 2017 | $608.20M | Oct 1, 2018 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $1.29B | Sep 26, 2025 |
| FY2025 | Jul 31, 2024 | $1.27B | Sep 26, 2025 |
| FY2025 | Jul 31, 2023 | $1.16B | Sep 26, 2025 |
| FY2024 | Jul 31, 2022 | $1.07B | Sep 27, 2024 |
| FY2023 | Jul 31, 2021 | $971.70M | Sep 22, 2023 |
| FY2020 | Jul 31, 2020 | $207.90M | Sep 25, 2020 |
| FY2020 | Apr 30, 2020 | $209.20M | Sep 25, 2020 |
| FY2020 | Jan 31, 2020 | $223.20M | Sep 25, 2020 |
| FY2020 | Oct 31, 2019 | $231.30M | Sep 25, 2020 |
| FY2020 | Jul 31, 2019 | $243.80M | Sep 25, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $367.00M | Sep 26, 2025 |
| FY2025 | Jul 31, 2024 | $414.00M | Sep 26, 2025 |
| FY2025 | Jul 31, 2023 | $358.80M | Sep 26, 2025 |
| FY2024 | Jul 31, 2022 | $332.80M | Sep 27, 2024 |
| FY2023 | Jul 31, 2021 | $286.90M | Sep 22, 2023 |
| FY2022 | Jul 31, 2020 | $257.00M | Sep 23, 2022 |
| FY2019 | Jul 31, 2019 | $58.00M | Sep 27, 2019 |
| FY2019 | Apr 30, 2019 | $75.20M | Sep 27, 2019 |
| FY2019 | Jan 31, 2019 | $60.10M | Sep 27, 2019 |
| FY2019 | Oct 31, 2018 | $73.80M | Sep 27, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $495.40M | Sep 26, 2025 |
| FY2025 | Jul 31, 2024 | $544.10M | Sep 26, 2025 |
| FY2025 | Jul 31, 2023 | $480.20M | Sep 26, 2025 |
| FY2024 | Jul 31, 2022 | $443.50M | Sep 27, 2024 |
| FY2023 | Jul 31, 2021 | $384.70M | Sep 22, 2023 |
| FY2022 | Jul 31, 2020 | $340.10M | Sep 23, 2022 |
| FY2021 | Jul 31, 2019 | $388.20M | Sep 24, 2021 |
| FY2020 | Jul 31, 2018 | $377.00M | Sep 25, 2020 |
| FY2019 | Jul 31, 2017 | $323.60M | Sep 27, 2019 |
| FY2018 | Jul 31, 2016 | $274.20M | Oct 1, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $87.80M | Sep 26, 2025 |
| FY2025 | Jul 31, 2024 | $93.60M | Sep 26, 2025 |
| FY2025 | Jul 31, 2023 | $78.10M | Sep 26, 2025 |
| FY2024 | Jul 31, 2022 | $69.10M | Sep 27, 2024 |
| FY2023 | Jul 31, 2021 | $67.80M | Sep 22, 2023 |
| FY2022 | Jul 31, 2020 | $61.20M | Sep 23, 2022 |
| FY2021 | Jul 31, 2019 | $62.30M | Sep 24, 2021 |
| FY2020 | Jul 31, 2018 | $59.90M | Sep 25, 2020 |
| FY2019 | Jul 31, 2017 | $54.70M | Sep 27, 2019 |
| FY2018 | Jul 31, 2016 | $55.50M | Oct 1, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $641.00M | Sep 26, 2025 |
| FY2025 | Jul 31, 2024 | $636.70M | Sep 26, 2025 |
| FY2025 | Jul 31, 2023 | $602.30M | Sep 26, 2025 |
| FY2024 | Jul 31, 2022 | $554.80M | Sep 27, 2024 |
| FY2023 | Jul 31, 2021 | $519.20M | Sep 22, 2023 |
| FY2022 | Jul 31, 2020 | $470.30M | Sep 23, 2022 |
| FY2021 | Jul 31, 2019 | $497.80M | Sep 24, 2021 |
| FY2011 | Jul 31, 2011 | $443.23M | Sep 23, 2011 |
| FY2011 | Jul 31, 2010 | $376.02M | Sep 23, 2011 |
| FY2011 | Jul 31, 2009 | $379.11M | Sep 23, 2011 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $418.80M | Sep 26, 2025 |
| FY2025 | Jul 31, 2024 | $492.50M | Sep 26, 2025 |
| FY2025 | Jul 31, 2023 | $544.50M | Sep 26, 2025 |
| FY2024 | Jul 31, 2022 | $252.80M | Sep 27, 2024 |
| FY2023 | Jul 31, 2021 | $401.90M | Sep 22, 2023 |
| FY2022 | Jul 31, 2020 | $387.00M | Sep 23, 2022 |
| FY2021 | Jul 31, 2019 | $345.80M | Sep 24, 2021 |
| FY2020 | Jul 31, 2018 | $262.90M | Sep 25, 2020 |
| FY2019 | Jul 31, 2017 | $317.80M | Sep 27, 2019 |
| FY2018 | Jul 31, 2016 | $291.30M | Oct 1, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $78.90M | Sep 26, 2025 |
| FY2025 | Jul 31, 2024 | $85.60M | Sep 26, 2025 |
| FY2025 | Jul 31, 2023 | $118.50M | Sep 26, 2025 |
| FY2024 | Jul 31, 2022 | $85.50M | Sep 27, 2024 |
| FY2023 | Jul 31, 2021 | $59.00M | Sep 22, 2023 |
| FY2022 | Jul 31, 2020 | $124.40M | Sep 23, 2022 |
| FY2021 | Jul 31, 2019 | $150.70M | Sep 24, 2021 |
| FY2020 | Jul 31, 2018 | $97.50M | Sep 25, 2020 |
| FY2019 | Jul 31, 2017 | $65.90M | Sep 27, 2019 |
| FY2018 | Jul 31, 2016 | $72.90M | Oct 1, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $2.98B | Sep 26, 2025 |
| FY2025 | Jul 31, 2024 | $2.91B | Sep 26, 2025 |
| FY2025 | Jul 31, 2023 | $2.77B | Sep 26, 2025 |
| FY2023 | Jul 31, 2022 | $2.60B | Sep 22, 2023 |
| FY2022 | Jul 31, 2021 | $2.40B | Sep 23, 2022 |
| FY2021 | Jul 31, 2020 | $2.24B | Sep 24, 2021 |
| FY2020 | Jul 31, 2019 | $2.14B | Sep 25, 2020 |
| FY2019 | Jul 31, 2018 | $1.98B | Sep 27, 2019 |
| FY2018 | Jul 31, 2017 | $1.98B | Oct 1, 2018 |
| FY2018 | Jul 31, 2016 | $1.79B | Oct 1, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $1.52B | Sep 26, 2025 |
| FY2025 | Jul 31, 2024 | $1.43B | Sep 26, 2025 |
| FY2024 | Jul 31, 2023 | $1.45B | Sep 27, 2024 |
| FY2023 | Jul 31, 2022 | $1.47B | Sep 22, 2023 |
| FY2022 | Jul 31, 2021 | $1.26B | Sep 23, 2022 |
| FY2021 | Jul 31, 2020 | $1.24B | Sep 24, 2021 |
| FY2020 | Jul 31, 2019 | $1.24B | Sep 25, 2020 |
| FY2019 | Jul 31, 2018 | $1.12B | Sep 27, 2019 |
| FY2018 | Jul 31, 2017 | $1.13B | Oct 1, 2018 |
| FY2017 | Jul 31, 2016 | $1.02B | Sep 22, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $1.45B | Sep 26, 2025 |
| FY2025 | Jul 31, 2024 | $1.49B | Sep 26, 2025 |
| FY2025 | Jul 31, 2023 | $1.32B | Sep 26, 2025 |
| FY2025 | Jul 31, 2022 | $1.13B | Sep 26, 2025 |
| FY2024 | Jul 31, 2021 | $1.14B | Sep 27, 2024 |
| FY2023 | Jul 31, 2020 | $992.90M | Sep 22, 2023 |
| FY2022 | Jul 31, 2019 | $892.70M | Sep 23, 2022 |
| FY2021 | Jul 31, 2018 | $857.80M | Sep 24, 2021 |
| FY2019 | Jul 31, 2017 | $854.50M | Sep 27, 2019 |
| FY2019 | Jul 31, 2016 | $771.40M | Sep 27, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $493.60M | Sep 26, 2025 |
| FY2025 | Jul 31, 2024 | $478.40M | Sep 26, 2025 |
| FY2025 | Jul 31, 2023 | $481.10M | Sep 26, 2025 |
| FY2024 | Jul 31, 2022 | $345.80M | Sep 27, 2024 |
| FY2023 | Jul 31, 2021 | $322.50M | Sep 22, 2023 |
| FY2022 | Jul 31, 2020 | $316.80M | Sep 23, 2022 |
| FY2021 | Jul 31, 2019 | $303.10M | Sep 24, 2021 |
| FY2020 | Jul 31, 2018 | $238.40M | Sep 25, 2020 |
| FY2019 | Jul 31, 2017 | $238.10M | Sep 27, 2019 |
| FY2018 | Jul 31, 2016 | $229.30M | Oct 1, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $2.61B | Sep 26, 2025 |
| FY2025 | Jul 31, 2024 | $2.38B | Sep 26, 2025 |
| FY2024 | Jul 31, 2023 | $2.09B | Sep 27, 2024 |
| FY2023 | Jul 31, 2022 | $1.85B | Sep 22, 2023 |
| FY2022 | Jul 31, 2021 | $1.61B | Sep 23, 2022 |
| FY2021 | Jul 31, 2020 | $1.43B | Sep 24, 2021 |
| FY2020 | Jul 31, 2019 | $1.28B | Sep 25, 2020 |
| FY2019 | Aug 1, 2018 | $1.13B | Sep 27, 2019 |
| FY2019 | Jul 31, 2018 | $1.12B | Sep 27, 2019 |
| FY2018 | Jul 31, 2017 | $1.04B | Oct 1, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $180.40M | Sep 26, 2025 |
| FY2025 | Jul 31, 2024 | $232.70M | Sep 26, 2025 |
| FY2024 | Jul 31, 2023 | $187.10M | Sep 27, 2024 |
| FY2023 | Jul 31, 2022 | $193.30M | Sep 22, 2023 |
| FY2022 | Jul 31, 2021 | $222.80M | Sep 23, 2022 |
| FY2021 | Jul 31, 2020 | $236.60M | Sep 24, 2021 |
| FY2020 | Jul 31, 2019 | $177.80M | Sep 25, 2020 |
| FY2019 | Jul 31, 2018 | $204.70M | Sep 27, 2019 |
| FY2019 | Jul 31, 2017 | $308.40M | Sep 27, 2019 |
| FY2019 | Jul 31, 2016 | $243.20M | Sep 27, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $640.00M | Sep 26, 2025 |
| FY2024 | Jul 31, 2024 | $510.00M | Sep 27, 2024 |
| FY2023 | Jul 31, 2023 | $623.40M | Sep 22, 2023 |
| FY2022 | Jul 31, 2022 | $646.70M | Sep 23, 2022 |
| FY2021 | Jul 31, 2021 | $463.30M | Sep 24, 2021 |
| FY2020 | Jul 31, 2020 | $625.00M | Sep 25, 2020 |
| FY2019 | Jul 31, 2019 | $634.60M | Sep 27, 2019 |
| FY2018 | Jul 31, 2018 | $514.90M | Oct 1, 2018 |
| FY2017 | Jul 31, 2017 | $587.90M | Sep 22, 2017 |
| FY2016 | Jul 31, 2016 | $403.00M | Sep 23, 2016 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | 3 | Sep 26, 2025 |
| FY2025 | Jul 31, 2024 | 3 | Sep 26, 2025 |
| FY2025 | Jul 31, 2023 | 2 | Sep 26, 2025 |
| FY2024 | Jul 31, 2022 | 2 | Sep 27, 2024 |
| FY2023 | Jul 31, 2021 | 2 | Sep 22, 2023 |
| FY2020 | Jul 31, 2020 | 0 | Sep 25, 2020 |
| FY2020 | Apr 30, 2020 | 0 | Sep 25, 2020 |
| FY2020 | Jan 31, 2020 | 0 | Sep 25, 2020 |
| FY2020 | Oct 31, 2019 | 0 | Sep 25, 2020 |
| FY2020 | Jul 31, 2019 | 0 | Sep 25, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | 3 | Sep 26, 2025 |
| FY2025 | Jul 31, 2024 | 3 | Sep 26, 2025 |
| FY2025 | Jul 31, 2023 | 2 | Sep 26, 2025 |
| FY2024 | Jul 31, 2022 | 2 | Sep 27, 2024 |
| FY2023 | Jul 31, 2021 | 2 | Sep 22, 2023 |
| FY2020 | Jul 31, 2020 | 0 | Sep 25, 2020 |
| FY2020 | Apr 30, 2020 | 0 | Sep 25, 2020 |
| FY2020 | Jan 31, 2020 | 0 | Sep 25, 2020 |
| FY2020 | Oct 31, 2019 | 0 | Sep 25, 2020 |
| FY2020 | Jul 31, 2019 | 0 | Sep 25, 2020 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Jul 31, 2025 | $131.90M | Sep 26, 2025 |
| FY2025 | Jul 31, 2024 | $122.80M | Sep 26, 2025 |
| FY2025 | Jul 31, 2023 | $114.40M | Sep 26, 2025 |
| FY2024 | Jul 31, 2022 | $110.10M | Sep 27, 2024 |
| FY2023 | Jul 31, 2021 | $107.20M | Sep 22, 2023 |
| FY2022 | Jul 31, 2020 | $106.40M | Sep 23, 2022 |
| FY2021 | Jul 31, 2019 | $99.70M | Sep 24, 2021 |
| FY2020 | Jul 31, 2018 | $94.70M | Sep 25, 2020 |
| FY2019 | Jul 31, 2017 | $92.40M | Sep 27, 2019 |
| FY2018 | Jul 31, 2016 | $91.20M | Oct 1, 2018 |